Stockscreener 앱 받기
104.54
0.32%
-0.34
Gilead Sciences Inc 주식(GILD)의 최신 뉴스
What Analyst Projections for Key Metrics Reveal About Gilead (GILD) Q1 Earnings - MSN
Here's Why Gilead Sciences (GILD) is a Strong Value Stock - Yahoo Finance
BMO Capital Adjusts Gilead Sciences Price Target to $120 From $115 - marketscreener.com
Leerink Partners Adjusts Price Target on Gilead Sciences to $105 From $104, Keeps Outperform Rating - MarketScreener
Gilead Sciences (GILD) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
News - Department of Health Abu Dhabi
DoH Partners with Gilead Sciences to propel healthcare innovation and cell therapy advancement - ZAWYA
Nurix Says FDA Clears Oral IRAK4 Degrader Application for Inflammatory Diseases; Shares Up Pre-Bell - marketscreener.com
2 High-Yielding ETFs Retirees Can Safely Build Their Portfolios Around - The Motley Fool
Gilead Sciences (GILD) Stock Moves -0.74%: What You Should Know - MSN
Gilead Sciences CFO sells $266,000 in stock - Investing.com
Gilead Sciences CFO sells $266,000 in stock By Investing.com - Investing.com India
Gilead Sciences: Advancing Oncology Care Through Gilead's Research Scholars Program - CSRwire
Gilead vs Bristol Myers: Which Biotech Bigwig is a Better Bet Now? - Yahoo Finance
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know - MSN
Is Gilead Sciences Inc. (NASDAQ:GILD) the Most Undervalued Quality Stock to Buy Now? - Insider Monkey
Bridgewater Associates LP Boosts Stake in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
11 Most Undervalued Quality Stocks to Buy Now - Insider Monkey
Lobbying Update: $75,000 of GILEAD SCIENCES INC. lobbying was just disclosed - Nasdaq
Goldman Sachs Adjusts Price Target on Gilead Sciences to $97 From $96, Maintains Neutral Rating - MarketScreener
Press Release Distribution & PR Platform - ACCESS Newswire
Revenues Working Against Gilead Sciences, Inc.'s (NASDAQ:GILD) Share Price - simplywall.st
GILD Stock Price and Chart — NASDAQ:GILD - TradingView
EPO board revives Gilead patent, sends case back for review - MLex
Gilead patent partially upheld by EPO, Teva and STADA's challenge continues - MLex
Here's What to Expect From Gilead Sciences’ Next Earnings Report - Nasdaq
Gilead reprimanded after PMCPA finds conference Wi-Fi sponsorship broke advertising rules - Fierce Pharma
Here's What To Expect From Gilead Sciences’ Next Earnings Report - Barchart.com
Gilead Sciences, Trusaic Data Breach Lawsuit Investigation - ClassAction.org
PatientView Ranks Gilead “Best” at ESG - CSRwire
Gilead Sciences Inc (GILD) Shares Gap Down to $100.87 on Apr 10 - GuruFocus
Gilead Sciences To Release First Quarter 2025 Financial Results On Thursday, April 24, 2025 - MarketScreener
Gilead Sciences Announces Q1 Estimated Acquired IPR&D - MarketScreener
Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025 | GILD Stock News - GuruFocus
Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025 - Business Wire
AI-startup Prezent names Gilead Sciences’ exec to Board - StartUp Beat
PatientView Ranks Gilead "Best" at ESG - MarketScreener
Gilead is urged to rework licensing deals for groundbreaking HIV prevention drug - statnews.com
Ideaya Biosciences Begins Phase 1/2 Expansion in Urothelial Cancer Treatment Trial in Combination With Gilead's Trodelvy - MarketScreener
Manufacturer’s plans for equitable access to twice-yearly PrEP under fire - Aidsmap
Mich. Panel: Gilead Immune From Recalled COVID Drug Suit - Law360
Gilead Sciences (GILD) Increases Yet Falls Behind Market: What Investors Need to Know - Yahoo Finance
Gilead, Michigan Hospital Win Appeal Over Tainted Covid-19 Drug - Bloomberg Law News
Gilead Sciences (GILD) Anticipates Earnings Surprise - GuruFocus
Will Gilead (GILD) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
AIDSVu Online Mapping Tool Helps Visualize HIV’s Impact in the United States - Gilead Sciences
Gilead Sciences: The Global Health Challenge of HIV and Hepatitis B Coinfections - CSRwire
Multiple Tailwinds Lifted Gilead Sciences (GILD) in Q1 - Insider Monkey
Weekly CFO Sells Highlight: Adobe Systems, Gilead Sciences and A - GuruFocus
July 18th Options Now Available For Gilead Sciences (GILD) - Nasdaq
Gilead Sciences describes new nucleoside prodrugs for viral infections - BioWorld MedTech
0.67%
1.89%
자본화:
|
볼륨(24시간):